SKP2 and plasma cell myeloma: Both in vitro and in vivo model results strongly suggest that a combination of novel drug SCF-SKP2 inhibitor (DT204) and BTZ triggered synergistic anti-myeloma activity in the xenograft myeloma mouse model.